NKGen Biotech, Inc. Common Stock (NKGN)
USD 0.49
(8.26%)
USD 0.49
(8.26%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | - | 77 Thousand | 426 Thousand |
| Cost of Revenue | 1.2 Million | 18 Thousand | 30 Thousand |
| Gross Profit | -1.2 Million | 59 Thousand | 396 Thousand |
| Operating Expenses | 28.54 Million | 24.4 Million | 22.25 Million |
| Selling, General and Administrative Expenses | 14.07 Million | 7.65 Million | 7.58 Million |
| Research and Development Expenses | 14.46 Million | 16.74 Million | 14.67 Million |
| Other Expenses | - | -95 Thousand | -84 Thousand |
| Cost and Expenses | 29.74 Million | 24.42 Million | 22.28 Million |
| Operating Income | -29.74 Million | -24.34 Million | -21.86 Million |
| Interest Expense | 745 Thousand | 2.3 Million | 1.31 Million |
| Income Tax Expense | 7000.00 | 7000.00 | 5000.00 |
| Earnings before Tax | -82.94 Million | -26.74 Million | -23.26 Million |
| Net Income | -82.95 Million | -26.75 Million | -23.26 Million |
| Earnings Per Share Basic | -5.38 | -4.21 | -1.08 |
| Earnings Per Share Diluted | -5.38 | -4.21 | -1.08 |
| Weighted Average Shares Outstanding | 15.42 Million | 6.35 Million | 21.45 Million |
| Weighted Average Shares Outstanding (Diluted) | 15.42 Million | 6.35 Million | 21.45 Million |
| Gross Margin | - | 0.77 | 0.93 |
| EBIT Margin | - | -295.99 | -48.59 |
| Profit Margin | - | -347.45 | -54.61 |
| EBITDA | -28.54 Million | -23.23 Million | -20.7 Million |
| Earnings Before Tax Margin | - | -316.18 | -51.32 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | 326 Thousand | 1.2 Million | 300 Thousand | 300 Thousand | - |
| Gross Profit | - | -326 Thousand | -1.2 Million | -300 Thousand | -300 Thousand | - |
| Operating Expenses | 7.45 Million | 7.29 Million | 28.54 Million | 9.13 Million | 6.9 Million | 2.67 Million |
| Selling, General and Administrative Expenses | 4.37 Million | 4.35 Million | - | 5.34 Million | 2.97 Million | 2.62 Million |
| Research and Development Expenses | 3.08 Million | 2.94 Million | - | 3.79 Million | 3.92 Million | - |
| Other Expenses | - | -497 Thousand | - | - | 1.74 Million | -50 Thousand |
| Cost and Expenses | 7.45 Million | 7.62 Million | 29.74 Million | 9.43 Million | 6.9 Million | 2.67 Million |
| Operating Income | -7.45 Million | -7.62 Million | -29.74 Million | -9.43 Million | -6.9 Million | -2.67 Million |
| Interest Expense | 647 Thousand | 1.06 Million | 745 Thousand | 438 Thousand | 211 Thousand | - |
| Income Tax Expense | 647 Thousand | 282.72 Thousand | 7000.00 | 7000.00 | -89 Thousand | 286.77 Thousand |
| Earnings before Tax | -16.08 Million | -5.38 Million | -82.94 Million | -33.59 Million | -33.17 Million | -1.54 Million |
| Net Income | -16.08 Million | -5.38 Million | -82.95 Million | -33.6 Million | -33.17 Million | -1.83 Million |
| Earnings Per Share Basic | -0.67 | -0.25 | - | -1.54 | -2.48 | -0.11 |
| Earnings Per Share Diluted | -0.67 | -0.25 | - | -1.54 | -2.48 | -0.11 |
| Weighted Average Shares Outstanding | 24.16 Million | 21.93 Million | 15.42 Million | 21.88 Million | 13.39 Million | 16.82 Million |
| Weighted Average Shares Outstanding (Diluted) | 24.16 Million | 21.93 Million | 15.42 Million | 21.88 Million | 13.39 Million | 16.82 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -7.13 Million | -7.29 Million | - | -9.13 Million | -6.9 Million | -2.67 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
SVII
PLMI
GGAZF
BONAV-B
AEDAS
NXS